Neuroprotective effect and mechanism of baicalin on Parkinson’s disease model induced by 6-OHDA

Código QR

Neuroprotective effect and mechanism of baicalin on Parkinson’s disease model induced by 6-OHDA

Li Tu,1 Zhuo-Yu Wu,2 Xiu-Lin Yang,3 Qian Zhang,3 Ran Gu,3 Qian Wang,2 Tian Tian,2 Huan Yao,3 Xiang Qu,3 Jin-Yong Tian2,3 1Department of General Medical, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China; 2Department of Neurology, Guizhou Provincial People’s Hos...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tu L, Wu ZY, Yang XL, Zhang Q, Gu R, Wang Q, Tian T, Yao H, Qu X, Tian JY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	parkinson disease neurotransmitter baicalin metabolomics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/4d30d80ffbb64bac8d1060deee8d497d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

DETERMINATION OF CHLOROGENIC ACID, BAICALIN AND FORSYTHIN IN SHUANGHUANGLIAN PREPARATIONS BY HPLC-DAD
por: YANG,LI, et al.
Publicado: (2012)

Preparation, Characterization and in vivo Study of Borneol-Baicalin-Liposomes for Treatment of Cerebral Ischemia-Reperfusion Injury
por: Zhang Y, et al.
Publicado: (2020)

Therapeutic value of the metabolomic active neurotransmitter isorhynchophylline in the treatment of spontaneously hypertensive rats by regulating neurotransmitters
por: Alharbi Homood, et al.
Publicado: (2021)

Baicalin suppresses autophagy-dependent ferroptosis in early brain injury after subarachnoid hemorrhage
por: Bao Zheng, et al.
Publicado: (2021)

Baicalin Enhanced Oral Bioavailability of Sorafenib in Rats by Inducing Intestine Absorption
por: Jingyao Wei, et al.
Publicado: (2021)

Odor selectivity of hyposmia and cognitive impairment in patients with Parkinson’s disease
por: Mao CJ, et al.
Publicado: (2017)

Transcriptome Sequencing Explores the Mechanism of Baicalin on Bone Cancer Pain
por: Wang A, et al.
Publicado: (2021)

Interictal Activity Is Associated With Slower Binocular Rivalry in Idiopathic Generalized Epilepsy
por: Jiaonan Wu, et al.
Publicado: (2021)

Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
por: Schettino C, et al.
Publicado: (2016)

The role of deep brain stimulation in Parkinson’s disease: an overview and update on new developments
por: Fang JY, et al.
Publicado: (2017)

The role of rasagiline in the treatment of Parkinson’s disease
por: Julie Leegwater-Kim, et al.
Publicado: (2010)

Parkinson's disease

Enfermedad de Alzheimer: Actualización en terapia farmacológica
por: Fuentes G,Patricio, et al.
Publicado: (2005)

Baicalin improves podocyte injury in rats with diabetic nephropathy by inhibiting PI3K/Akt/mTOR signaling pathway
por: Ou Yi, et al.
Publicado: (2021)

Neuropsychiatric symptoms in untreated Parkinson’s disease
por: Szatmari S, et al.
Publicado: (2017)

Systematic review on strength training in Parkinson’s disease: an unsolved question
por: Ramazzina I, et al.
Publicado: (2017)

Study of Baicalin toward COVID-19 Treatment: In silico Target Analysis and in vitro Inhibitory Effects on SARS-CoV-2 Proteases
por: Chingju Lin, et al.
Publicado: (2021)

Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis
por: Zhang H, et al.
Publicado: (2019)

Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
por: Combs BL, et al.
Publicado: (2017)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Werner Poewe, et al.
Publicado: (2010)

Cytological and cytometric analysis of oral mucosa in patients with Alzheimer’s and Parkinson’s disease
por: Kose Ozlece H, et al.
Publicado: (2018)

Parkinson’s disease managing reversible neurodegeneration
por: Hinz M, et al.
Publicado: (2016)

Sleep apnea leading to Parkinson’s disease – an important association
por: Shafqat MN, et al.
Publicado: (2017)

Parkinson’s Disease Managing Reversible Neurodegeneration [Retraction]
por: Hinz M, et al.
Publicado: (2020)

Psychosis in parkinsonism: an unorthodox approach
por: Onofrj M, et al.
Publicado: (2017)

Neuroprotective Potential of Polydatin Against Motor Abnormalities and Dopaminergic Neuronal Loss in Rotenone Induced Parkinson Model
por: Ahmed,Muhammad Rashid, et al.
Publicado: (2018)

The efficacy of a “cocktail therapy” on Parkinson’s disease with dementia
por: Zhang C, et al.
Publicado: (2019)

Clinical study of the effects of deep brain stimulation on urinary dysfunctions in patients with Parkinson’s disease
por: Zong H, et al.
Publicado: (2019)

Journal of Parkinson's disease

Altered emotional recognition and expression in patients with Parkinson’s disease
por: Jin Y, et al.
Publicado: (2017)

Parkinson’s Disease Managing Reversible Neurodegeneration [Expression of Concern]
por: Hinz M, et al.
Publicado: (2020)

Synaptic Density and Neuronal Metabolic Function Measured by Positron Emission Tomography in the Unilateral 6-OHDA Rat Model of Parkinson’s Disease
por: Nakul Ravi Raval, et al.
Publicado: (2021)

Regional Neural Activity Changes in Parkinson’s Disease-Associated Mild Cognitive Impairment and Cognitively Normal Patients
por: Xing Y, et al.
Publicado: (2021)

Systematic review of the prevalence and incidence of Parkinson’s disease in the People’s Republic of China
por: Zou YM, et al.
Publicado: (2015)

A practical method for the detection of freezing of gait in patients with Parkinson’s disease
por: Kwon Y, et al.
Publicado: (2014)

Different protocols for analyzing behavior and adaptability in obstacle crossing in Parkinson’s disease
por: Mollaei N, et al.
Publicado: (2017)

Assessment of cognitive impairment in patients with Parkinson's disease: prevalence and risk factors
por: Wang Q, et al.
Publicado: (2014)

Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden
por: Modugno N, et al.
Publicado: (2020)

Progressive Resistance Training Improves Bradykinesia, Motor Symptoms and Functional Performance in Patients with Parkinson’s Disease
por: Vieira de Moraes Filho A, et al.
Publicado: (2020)

Minimum Alveolar Concentration-Awake of Sevoflurane is Decreased in Patients with Parkinson’s Disease: An Up-and-Down Sequential Allocation Trial
por: Yang C, et al.
Publicado: (2021)